Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Neoplasms
Interventions: DRUG: BAY94-9343
Sponsor: Bayer